Tetra Bio-Pharma (TBPMF) Stock Price, News & Analysis

Company Overview

Tetra Bio-Pharma Inc is a clinical-stage specialty pharmaceutical company headquartered in Laval, Quebec. The company focuses on the discovery, development and commercialization of plant-derived cannabinoid-based therapies for pain, inflammation and supportive care. Tetra Bio-Pharma’s research platform explores novel drug delivery technologies designed to optimize the safety, tolerability and efficacy of cannabinoid compounds in human disease.

The company’s pipeline includes an extended-release oral THC formulation for chemotherapy-induced nausea and vomiting, an oral cannabinoid formulation targeting neuropathic pain, and an intravenous formulation for acute pain management. These candidates have advanced through various stages of clinical development, with ongoing trials designed to generate safety and efficacy data in collaboration with academic and clinical research organizations. Tetra Bio-Pharma also holds patents covering its proprietary formulations and manufacturing processes.

In addition to its proprietary drug programs, Tetra Bio-Pharma operates Tetra Discovery Labs, a fully licensed, GMP-certified research and manufacturing facility that offers contract development services to pharmaceutical and biotechnology companies. Through this subsidiary, the company provides analytical testing, formulation development and pilot-scale manufacturing support to external clients, while maintaining capacity for its internal pipeline projects.

Tetra Bio-Pharma currently markets a range of over-the-counter cannabinoid-based products in Canada under its consumer wellness portfolio. The company has established distribution partnerships across North America and is pursuing licensing and joint-venture agreements in Europe, Latin America and Asia. Under the leadership of CEO Michael Frank, Tetra Bio-Pharma continues to expand its global footprint and advance its clinical programs toward regulatory approvals.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 185,753 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TBPMF
• CIK: N/A
• Web: www.tetrabiopharma.com
• Phone: (833) 977-7575
• Fax: N/A
• Employees: 33
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A